2015 Fiscal Year Final Research Report
Development of a therapeutic drug for bone-related diseases based on chemical genetics
| Project/Area Number |
26750373
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Chemical biology
|
|---|
| Research Institution | Juntendo University (2015)
Keio University (2014) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Keywords | ケミカルジェネティクス / 骨粗鬆症 / 破骨細胞 |
|---|
| Outline of Final Research Achievements |
In order to identify a new therapeutic drug for bone-related diseases, we screened for small-molecules that inhibit osteoclast differentiation. We found that a novel compound, SUKU-1, suppressed RANKL-induced osteoclastogenesis. We also synthesized 38 derivatives of SUKU-1 and identified SUKU-33 as a most potent inhibitor. We found SUKU-33 suppressed RANKL-induced expression of osteoclast-related genes. By measuring the uptake of [3H]-uridine, we found that SUKU-33 inhibited transport of nucleoside via both equilibrative nucleoside transporters and concentrative nucleoside transporters. These results suggest that SUKU-33 inhibits osteoclastogenesis by suppressing nucleoside transporters.
|
| Free Research Field |
ケミカルバイオロジー
|
